Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

This publication has 50 references indexed in Scilit:

• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
  Blood, 2008
• The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
  British Journal of Haematology, 2008
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
  New England Journal of Medicine, 2007
• Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
  New England Journal of Medicine, 2007
• Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
  Journal of Clinical Oncology, 2007
• High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
  Blood, 2007
• Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
  The Lancet, 2006
• Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
  Blood, 2005
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
  British Journal of Haematology, 1998